Today: 21 May 2026
Browse Category

NYSE:TGT 29 December 2025 - 20 May 2026

Target’s Turnaround Finally Has Numbers Wall Street Can’t Ignore

Target’s Turnaround Finally Has Numbers Wall Street Can’t Ignore

Target raised its annual sales forecast after first-quarter net sales rose 6.7% to $25.44 billion, ending a three-year revenue slide. Comparable sales increased 5.6%, with digital up 8.9%. Profit fell to $781 million from $1.04 billion a year earlier. New CEO Michael Fiddelke cited progress but maintained a cautious outlook amid ongoing investment and price cuts.
20 May 2026
Dow edges up while Nasdaq falls as bond worries drag on

Dow edges up while Nasdaq falls as bond worries drag on

The Dow rose 0.22% to 49,637.04 late Monday morning, while the S&P 500 slipped 0.15% and the Nasdaq fell 0.44%. The 10-year Treasury yield dropped to 4.573% after hitting its highest since February 2025. Dominion Energy shares jumped after NextEra agreed to buy it for about $66.8 billion. Regeneron fell as a melanoma drug trial missed its main goal.
Markets Drop Fed Rate Cut Bets for 2026

Markets Drop Fed Rate Cut Bets for 2026

Prediction-market odds for no Federal Reserve rate cuts in 2026 jumped to 69% on Polymarket and 68% on Kalshi. U.S. stocks fell over 1% Friday as oil prices and Treasury yields climbed, pressuring technology shares. CME FedWatch now shows a 60% chance of higher rates by January. Near-term markets still expect no change at the June Fed meeting.
Nvidia, Walmart, and Big Utility Deal Set for Monday Trading

Nvidia, Walmart, and Big Utility Deal Set for Monday Trading

NextEra Energy and Dominion Energy are in merger talks on a stock deal that could create a $400 billion utility, Reuters reported, citing the Financial Times. U.S. stocks fell over 1% Friday as oil prices and Treasury yields climbed. Nvidia reports earnings Wednesday after a 36% rally since March. Kalshi and Polymarket data show little expectation of a June Fed rate move.
Target’s selloff says the turnaround rally now has to prove itself

Target’s selloff says the turnaround rally now has to prove itself

Target shares fell 5.44% to $118.44 Monday, marking their steepest one-day drop since August as investors grew cautious ahead of the May 20 earnings report. The decline followed a rally and came amid sector pressure, with 67 of 74 retail ETF components also down. Wall Street questioned whether Target’s rebound outpaced improvements in sales and store traffic. CEO Michael Fiddelke’s turnaround efforts faced renewed scrutiny.
12 May 2026
Self-Checkout Crackdown: New Grocery Bills Put Walmart, Target And Costco On Notice

Self-Checkout Crackdown: New Grocery Bills Put Walmart, Target And Costco On Notice

Massachusetts lawmakers advanced a bill to cap grocery self-checkout stations at eight per store and require more staffed lanes, legislative records show. Rhode Island has similar bills in committee. Connecticut’s version failed this month. Retailers including Target and Walmart have already adjusted checkout options amid concerns over theft and labor costs.
Target’s $2 billion turnaround bet: new CEO flags a path back to growth

Target’s $2 billion turnaround bet: new CEO flags a path back to growth

Target will invest an additional $2 billion in 2026, raising total capital spending to about $5 billion and planning over 30 new stores and 130 remodels. Fourth-quarter net sales fell 1.5% to $30.45 billion, with comparable sales down 2.5%. Shares jumped nearly 7% after the outlook, reaching a one-year high. Target forecasts 2026 earnings of $7.50–$8.50 per share on about 2% net sales growth.
4 March 2026
US stocks slide as oil jumps and today’s economic calendar stays light; Target up, MongoDB plunges

US stocks slide as oil jumps and today’s economic calendar stays light; Target up, MongoDB plunges

The Dow Jones fell 831.86 points, or 1.7%, Tuesday as oil prices jumped over 7% amid escalating U.S.-Israeli conflict with Iran. Brent crude rose $6.07 to $83.81 a barrel, while U.S. 10-year Treasury yields touched 4.10%. Traders pushed back expectations for Fed rate cuts to September. Target shares gained 6% after reporting $30.5 billion in quarterly sales.
Walmart stock price slips as tariff threats return and PhonePe IPO nod lands

Walmart stock price slips as tariff threats return and PhonePe IPO nod lands

Walmart shares fell 0.4% to $118.27 Wednesday after new U.S. tariffs and a Reuters report on Walmart’s India investments. President Trump announced a 10% tariff on imports from eight European countries starting Feb. 1, rising to 25% by June. Walmart-backed PhonePe received approval to pursue an IPO by mid-2026. Investors await Walmart’s Feb. 19 earnings report.
Amazon stock slides after Jassy warns tariffs are creeping into prices

Amazon stock slides after Jassy warns tariffs are creeping into prices

Amazon shares fell 3.4% to $231 in after-hours trading Tuesday after CEO Andy Jassy warned tariffs are starting to lift prices and dampen demand. U.S. tariff threats from President Trump rattled markets, sending the S&P 500 ETF down 2.1%. Investors are watching Amazon’s Feb. 5 earnings for signs of further impact. Walmart and Target also declined.
Google’s new Gemini “buy button” aims to keep shoppers — and retailers — inside its AI

Google’s new Gemini “buy button” aims to keep shoppers — and retailers — inside its AI

Alphabet shares rose about 1% premarket after Google launched new AI shopping tools and the Universal Commerce Protocol, partnering with Walmart, Shopify, and others. The protocol enables direct checkout in Search and Gemini, with retailers keeping transaction control. Walmart will let shoppers add products to carts via Gemini conversations. The rollout follows similar AI shopping moves by Amazon and OpenAI.
Costco closed on New Year’s Day: New Year’s Eve 2025 store hours for Walmart, Aldi, Tesco and more

Costco closed on New Year’s Day: New Year’s Eve 2025 store hours for Walmart, Aldi, Tesco and more

Aldi, Costco, and Trader Joe’s will close U.S. stores on Jan. 1, with shortened hours on New Year’s Eve. Walmart plans normal hours, while Target and Walgreens may limit some locations. U.S. stock markets and FedEx services will halt Jan. 1. In Britain, Tesco, Sainsbury’s, Aldi, and Lidl will adjust hours or close for the bank holiday.
Target stock slips today as activist pressure stays in focus — what investors are watching next

Target stock slips today as activist pressure stays in focus — what investors are watching next

Target shares fell 0.7% to $97.38 in midday trading Tuesday, underperforming a weaker retail sector. The move follows reports that hedge fund Toms Capital Investment Management has taken a significant, undisclosed stake as Target prepares for a CEO transition in February. Investors await filings that could reveal TCIM’s intentions. Target shares are down more than 28% in 2025.
30 December 2025
Target stock drops after activist buzz fades; Fed minutes set the next test for TGT

Target stock drops after activist buzz fades; Fed minutes set the next test for TGT

Target fell 1.4% to $98.10 Monday, erasing part of last week’s activist-driven gains as trading volume stayed light. The move followed news that Toms Capital took a significant but undisclosed stake. Investors await Tuesday’s Fed minutes and any updates from the activist investor. Target has no investor events scheduled before its next earnings report, expected in early March.
Target stock ticks up in premarket as activist stake report keeps pressure on turnaround

Target stock ticks up in premarket as activist stake report keeps pressure on turnaround

Target shares rose 0.3% to $99.87 in premarket trading Monday after reports that Toms Capital Investment Management built a stake in the retailer. Investors await details on the activist fund’s plans as Target prepares for a CEO transition in February. The stock has dropped over 28% this year after three straight quarters of falling comparable sales. Target said its priority is returning to growth; Toms Capital declined to comment.
29 December 2025
1 2 3

Stock Market Today

  • Installed Building Products Stock: Revenue and Earnings Growth Slow Amid Market Underperformance
    May 20, 2026, 10:53 PM EDT. Installed Building Products' stock fell 15.9% to $208.38 over six months, underperforming the S&P 500's 13.3% gain. The slowdown in revenue growth to 2.4% annualized over two years contrasts with a 5-year trend of 11.7%. Earnings per share growth also lagged at 2.6%, reflecting persistent but subdued profitability. The stock trades at a forward price-to-earnings ratio of 20.8, indicating a fair valuation but limited near-term optimism. Analysts highlight a cautious outlook due to softer quarterly results and unproven impact from new offerings, suggesting investors may find better opportunities elsewhere.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop